Agarwal Shefali
Director at FATE; Officer at Epizyme, Inc.
- Sold, on record
- $293k
- Dollars the filings state
- Form 4 sales
- 13
- Latest Jun 7, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- FATEFATE THERAPEUTICS INCDirector
- Epizyme, Inc.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Epizyme, Inc.23,478 shares
- FATE1,648 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Epizyme, Inc.Plan not statedJan 25 2021
Sold 2,872 shares at $11.41 ($33k)
Agarwal Shefali, Chief Medical Officer
Sold 3.7% of holdings ($897k position)75,727 shares left1.6x usual sizeFiling
- 2 Form 4 sale Epizyme, Inc.Plan not statedFeb 4 +10 days
Sold 969 shares at $11.21 ($11k)
Agarwal Shefali, Chief Medical Officer
Sold 0.9% of holdings ($1.2M position)104,341 shares left0.4x usual sizeFiling
- 3 Form 4 sale Epizyme, Inc.Plan not statedDec 6 +305 days
Sold 1,780 shares at $2.93 ($5k)
Agarwal Shefali, Officer
Sold 1.1% of holdings ($483k position)163,004 shares left0.8x usual sizeFiling
- 4 Form 4 sale Epizyme, Inc.Plan not statedJan 26 +51 days
Sold 2,922 shares at $2.02 ($6k)
Agarwal Shefali, Officer
Sold 1.8% of holdings ($329k position)160,082 shares left1.6x usual sizeFiling
- 5 Form 4 sale Epizyme, Inc.Plan not statedFeb 2 +7 days
Sold 2,639 shares at $1.37 ($4k)
Agarwal Shefali, Officer
Sold 1.6% of holdings ($219k position)157,443 shares left1.5x usual sizeFiling
- 6 Form 4 sale Epizyme, Inc.Plan not statedFeb 7 +5 days
Sold 1,058 shares at $1.50 ($2k)
Agarwal Shefali, Officer
Sold 0.7% of holdings ($236k position)156,385 shares left0.5x usual sizeFiling
- 7 Form 4 sale FATEUnusualJun 3 +116 days
Sold 807 shares at $22.80 ($18k)
Agarwal Shefali, Director
Sold 30.1% of holdings ($61k position)1,874 shares leftFirst sale on recordFiling
- 8 Form 4 sale FATEUnusualJun 7 +4 days
Sold 841 shares at $21.89 ($18k)
Agarwal Shefali, Director
Sold 31.4% of holdings ($59k position)1,840 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (13)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 7, 2022 | FATE | Director | Form 4 sale | 841 | $18k | 31.4% | Unusual | SEC |
| Jun 3, 2022 | FATE | Director | Form 4 sale | 807 | $18k | 30.1% | Unusual | SEC |
| Feb 7, 2022 | Epizyme, Inc. | Officer | Form 4 sale | 1,058 | $2k | 0.7% | Plan not stated | SEC |
| Feb 2, 2022 | Epizyme, Inc. | Officer | Form 4 sale | 2,639 | $4k | 1.6% | Plan not stated | SEC |
| Jan 26, 2022 | Epizyme, Inc. | Officer | Form 4 sale | 2,922 | $6k | 1.8% | Plan not stated | SEC |
| Dec 6, 2021 | Epizyme, Inc. | Officer | Form 4 sale | 1,780 | $5k | 1.1% | Plan not stated | SEC |
| Feb 4, 2021 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 969 | $11k | 0.9% | Plan not stated | SEC |
| Jan 25, 2021 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 2,872 | $33k | 3.7% | Plan not stated | SEC |
| Dec 3, 2020 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 2,522 | $34k | 3.2% | Plan not stated | SEC |
| Jun 26, 2020 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 1,805 | $29k | 2.2% | Plan not stated | SEC |
| Mar 25, 2020 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 1,243 | $19k | 1.7% | Plan not stated | SEC |
| Jan 27, 2020 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 4,473 | $99k | 7.1% | Plan not stated | SEC |
| Jun 14, 2019 | Epizyme, Inc. | Chief Medical Officer | Form 4 sale | 1,195 | $14k | 3.2% | Plan not stated | SEC |